SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Karaiskos Ilias)
 

Search: WFRF:(Karaiskos Ilias) > (2016) > Challenge for highe...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration

Karaiskos, Ilias (author)
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece.;Hygeia Gen Hosp, 4 Erythrou Stavrou Str & Kifisias, Athens 15123, Greece.
Friberg, Lena E (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Galani, Lambrini (author)
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece.
show more...
Ioannidis, Konstantinos (author)
Hygeia Gen Hosp, 4 Erythrou Stavrou Str & Kifisias, Athens 15123, Greece.
Katsouda, Emmanouela (author)
Hygeia Gen Hosp, Intens Care Unit, Athens, Greece.
Athanassa, Zoe (author)
Hygeia Gen Hosp, Intens Care Unit, Athens, Greece.
Paskalis, Harris (author)
Hygeia Gen Hosp, Intens Care Unit, Athens, Greece.
Giamarellou, Helen (author)
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece.
show less...
Hygeia Gen Hosp, Dept Internal Med 6, Athens, Greece;Hygeia Gen Hosp, 4 Erythrou Stavrou Str & Kifisias, Athens 15123, Greece. Institutionen för farmaceutisk biovetenskap (creator_code:org_t)
Elsevier BV, 2016
2016
English.
In: International Journal of Antimicrobial Agents. - : Elsevier BV. - 0924-8579 .- 1872-7913. ; 48:3, s. 337-341
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Traditionally, reduced daily doses of colistin methanesulphonate (CMS) in critically ill patients receiving continuous venovenous haemodiafiltration (CVVHDF) have resulted in suboptimal colistin concentrations. The necessity of a loading dose (LD) at treatment initiation has been proposed. A LD of 9 million IU (MU) [ca. 270 mg of colistin base activity (CBA)] was administrated with a maintenance dose of 4.5 MU (ca. 140 mg CBA) every 12 h (q12h) to eight critically ill patients receiving renal replacement therapy. Blood samples were collected immediately before and at different time intervals after the LD and the fourth dose, whilst pre-filter and post-filter blood samples were also collected. CMS and colistin concentrations were determined using an LC-MS/MS assay. Median maximum observed concentrations after the LD were 22.1 mg/L for CMS and 1.55 mg/L for colistin, whereas during maintenance dosing the corresponding values were 12.6 mg/L and 1.72 mg/L, respectively. CVVHDF clearance was determined as 2.98 L/h for colistin, equivalent to 62% of total apparent colistin clearance in CVVHDF patients. Both CMS and colistin were cleared by CVVHDF. Application of a LD of 9 MU CMS resulted in more rapid achievement of the target colistin concentration. Following implementation of a predicted pharmacokinetic model on plasma CMS/colistin concentrations, a LD of 12 MU CMS appears more appropriate, whilst a CMS maintenance dosage of at least 6.5-7.5 MU q12h is suggested in patients undergoing CVVHDF. However, further clinical studies are warranted to assess the safety of a LD of 12 MU CMS in patients receiving CVVHDF.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Keyword

Colistin
CMS
Loading dose
Pharmacokinetics
CVHHDF

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view